La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Leap Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Leap Therapeutics..

Leap Therapeutics (NASDAQ:LPTX) Azioni, Catena delle Opzioni

Leap Therapeutics

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Leap Therapeutics Inc

<p>HC Wainwright &amp; Co.  analyst Swayampakula Ramakanth   reiterates CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) with a Buy and maintains $11 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

CLGN

HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target

<p>DA Davidson  analyst Linda Bolton Weiser   maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Neutral and raises the price target from $70 to $87.</p>


PLNT

DA Davidson Maintains Neutral on Planet Fitness, Raises Price Target to $87

<p><strong>Laser Photonics Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) launched a research and development initiative to create laser solutions for pharmaceutical tablet drilling, wafer <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42241997/laser-photonics-launches-r-d-initiative-to-accelerate-innovation" rel="noreferrer noopener">scribing, and semiconductor marking</a>.</p>
<p>Laser Photonics is targeting pharmaceuticals, wafers, and semiconductors through its latest R&amp;D initiative. Following its&nbsp;recent acquisition&nbsp;of&nbsp;Control Micro Systems, the company is committing resources to several new engineering projects to continue advancing its newly acquired laser systems.&nbsp;</p>
<p>In pharmaceuticals, the company plans to advance Control Micro Systems&#8217; tablet drilling and marking system for time-release medications.</p>
<p>This Class I automated CO2 laser system includes a custom tablet fixture, fume extraction, and machine vision inspection for quality control, offering an effective anti-counterfeiting solution.</p>
<p>Laser technology for wafer serialization involves marking, scribing, and lapping silicon and related compound wafers.</p>
<p>The company plans to enhance Control Micro Systems' multi-station system, designed for wafers up to 300 mm wide and 300–800 microns thick, featuring robotic wafer positioning.</p>
<p>This technology supports production and tracking for applications such as consumer electronics, solar panels, LEDs, MEMS devices, and optoelectronic components.</p>
<p>Laser Photonics will also advance Control Micro Systems&#8217; semiconductor laser marking system, featuring a high-precision ultraviolet laser and galvanometer scanhead for rapid fiducial recognition.</p>
<p>This system creates small, permanent markings on IC mold compounds and ceramics with minimal heat, preventing damage to components. Integrated machine vision ensures accurate chip positioning and marking alignment.</p>
<p>This week, Laser Photonics opened pre-orders for its upcoming CleanTech Industrial <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42210836/laser-photonics-commences-pre-orders-for-industry-leading-pulsed-laser-cleaning-system" rel="noreferrer noopener">Roughening Laser 3060 (CTIR-3060)</a>.</p>
<p><strong>Price Action</strong>: LASE shares are up 0.36% at $5.63 at the last check Friday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com//node/42244572" target="_blank" rel="noreferrer noopener">Cannabis-Focused RIV Capital Reports 186% YoY Surge In Q3 Revenue Ahead Of Major Merger That Will Cover 25% Of US Population</a></strong></li>
</ul>
<p><em>Image via Unsplash.</em></p>


Equities

Small Cap

LASE

From Pills To Wafers: Laser Photonics Unveils R&D Initiative For Anti-Counterfeiting And High-Tech Manufacturing

<p>CLSA  analyst Baden Moore   initiates coverage on Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Underperform rating.</p>


Initiation

CLSA Initiates Coverage On Newmont with Underperform Rating

<p>Wedbush  analyst Daniel Ives   reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and maintains $300 price target.</p>


AAPL

Wedbush Reiterates Outperform on Apple, Maintains $300 Price Target

WIIM

APVO

Aptevo Therapeutics shares are trading lower after the company announced a 1-for-37 reverse stock split.

<p>Canaccord Genuity  analyst George Gianarikas   maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Buy and lowers the price target from $37 to $34.</p>


FLNC

Canaccord Genuity Maintains Buy on Fluence Energy, Lowers Price Target to $34

<p><strong>Tesla, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading higher<a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener"> Friday morning.</a></p>
<p>Tesla China shortened its payment cycle to supply chain partners to just 90 days in 2024, down from 100 days in 2023, according to <strong>Grace Tao</strong>, Tesla&#8217;s vice president of External Affairs, <a href="https://cnevpost.com/2024/11/28/tesla-china-payment-cycle-to-suppliers-90-days/" target="_blank" rel="noreferrer noopener">reported</a> CnEV Post.</p>
<p>Tao shared the update in a Weibo post, noting that four other unnamed new energy vehicle (NEV) makers still take over 150 days to settle payments.</p>
<p>This improvement is part of Tesla&#8217;s efforts to streamline operations and enhance supplier relationships.</p>
<p><strong>See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/24/11/42156817/tesla-rivian-settle-battery-tech-theft-dispute-after-nearly-4-years?itm_source=parsely-api" rel="noreferrer noopener">Tesla, Rivian Signal End To 4-Year Legal Battle Over Alleged Trade Secrets Theft</a></strong></p>
<p>Meanwhile, the EV behemoth revamped its referral program across North America as it races to a <a href="https://www.benzinga.com/news/24/10/41443856/tesla-offers-discounts-of-up-to-4k-on-select-model-3-y-vehicles-as-it-looks-to-avert-1st-ever-declin" target="_blank" rel="noreferrer noopener">delivery target of 515,000 vehicles</a> in the<a href="https://www.benzinga.com/markets/24/11/42207185/tesla-sweetens-referral-program-allowing-customers-to-earn-up-to-10000-as-elon-musks-ev-giant-races-to-500k-q4-delivery-target" target="_blank" rel="noreferrer noopener"> fourth quarter.</a> Tesla&#8217;s updated referral program includes enhanced discounts and rewards, with specific incentives for the Cybertruck.</p>
<p>The company recently started offering unlimited overnight charging via the&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/42081589/tesla-electric-offers-unlimited-overnight-charging-for-just-5-a-month-as-ev-giant-races-toward-5" rel="noreferrer noopener">Tesla Electric service</a>, down from $15 a month, aiming to attract more buyers.</p>
<p>This follows&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/10/41443856/tesla-offers-discounts-of-up-to-4k-on-select-model-3-y-vehicles-as-it-looks-to-avert-1st-ever-declin" rel="noreferrer noopener">discounts of up to $4,000</a> on select&nbsp;Model 3 and Model Y&nbsp;vehicles to avoid a decline in annual deliveries.</p>
<p>Despite these efforts,&nbsp;<a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher" target="_blank" rel="noreferrer noopener">analysts predict</a> that Tesla's fourth-quarter deliveries will set new records but may not prevent a yearly sales decline. The&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction" target="_blank" rel="noreferrer noopener">potential removal of the $7,500 EV tax credit</a>&nbsp;by the incoming Trump administration could further affect Tesla's sales, as highlighted by&nbsp;<a href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math" target="_blank" rel="noreferrer noopener">Gary Black</a>, who warns of significant earnings impact if the credit is cut.</p>
<p><strong>TSLA</strong> <strong>Price Action</strong>: Tesla shares are trading higher by 2.51% to $341.18 at publication Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/24/11/42160725/tesla-faces-environmental-violations-as-elon-musks-doge-prepares-for-garbage-collection-of-rules-that-dont-make-sense-report?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Faces Environmental Violations As Elon Musk's ‘DOGE' Prepares For ‘Garbage Collection Of Rules That Don&#8217;t Make Sense</a></strong></li>
</ul>
<p><em>Photo: Courtesy Tesla</em></p>


Global

Markets

Movers

General

TSLA

Tesla China Shortens Payment Cycle To 90 Days In 2024: Report

<p>Financial giants have made a conspicuous bullish move on ASML Holding. Our analysis of options history for ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) revealed 82 unusual trades.</p>
<p>Delving into the details, we found 57% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 29 were puts, with a value of $2,588,601, and 53 were calls, valued at $4,795,957.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $580.0 to $800.0 for ASML Holding over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of ASML Holding stands at 313.4, with a total volume reaching 6,778.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ASML Holding, situated within the strike price corridor from $580.0 to $800.0, throughout the last 30 days.</p>
<h3>ASML Holding 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732894317_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ASML</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$87.7</td>
<td>$86.9</td>
<td>$86.9</td>
<td>$760.00</td>
<td>$191.1K</td>
<td align="right">231</td>
<td align="right">22</td>
</tr>
<tr>
<td>ASML</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$86.8</td>
<td>$86.0</td>
<td>$86.0</td>
<td>$760.00</td>
<td>$189.2K</td>
<td align="right">231</td>
<td align="right">66</td>
</tr>
<tr>
<td>ASML</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$86.3</td>
<td>$85.5</td>
<td>$85.5</td>
<td>$750.00</td>
<td>$188.1K</td>
<td align="right">37</td>
<td align="right">66</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$41.2</td>
<td>$40.8</td>
<td>$41.2</td>
<td>$680.00</td>
<td>$168.9K</td>
<td align="right">334</td>
<td align="right">281</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$21.7</td>
<td>$20.9</td>
<td>$21.5</td>
<td>$690.00</td>
<td>$150.5K</td>
<td align="right">347</td>
<td align="right">75</td>
</tr>
</tbody>
</table>
</p>
<h3>About ASML Holding</h3>
<p>ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's main clients are TSMC, Samsung, and Intel.</p>
<p>Following our analysis of the options activities associated with ASML Holding, we pivot to a closer look at the company's own performance.</p>
<h3>ASML Holding's Current Market Status</h3>
<ul>
<li>With a trading volume of 550,696, the price of ASML is up by 3.75%, reaching $695.64.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for ASML Holding</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $767.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Bernstein persists with their Outperform rating on ASML Holding, maintaining a target price of $767. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ASML Holding, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

ASML

ASML Holding's Options Frenzy: What You Need to Know

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Tesla</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TSLA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 204 uncommon options trades for Tesla.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 47% bullish and 38%, bearish.</p>
<p>Out of all of the special options we uncovered, 54 are puts, for a total amount of $3,650,355, and 150 are calls, for a total amount of $11,585,823.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $700.0 for Tesla during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Tesla's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tesla's whale trades within a strike price range from $5.0 to $700.0 in the last 30 days. </p>
<h3>Tesla Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732894311_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$15.75</td>
<td>$15.3</td>
<td>$15.55</td>
<td>$330.00</td>
<td>$262.7K</td>
<td>3.4K</td>
<td>1.3K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$340.00</td>
<td>$171.3K</td>
<td>13.0K</td>
<td>65.1K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$5.9</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$335.00</td>
<td>$152.1K</td>
<td>7.8K</td>
<td>13.2K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$12.0</td>
<td>$11.7</td>
<td>$12.0</td>
<td>$330.00</td>
<td>$147.6K</td>
<td>10.8K</td>
<td>6.5K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.65</td>
<td>$2.64</td>
<td>$2.64</td>
<td>$485.00</td>
<td>$131.2K</td>
<td>175</td>
<td>2.7K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Tesla</h3>
<p>Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2023 were a little over 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.</p>
<p>Having examined the options trading patterns of Tesla, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Tesla</h3>
<ul>
<li>With a trading volume of 11,096,249, the price of TSLA is up by 1.86%, reaching $339.07.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tesla</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $317.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wedbush keeps a Outperform rating on Tesla with a target price of $400.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Tesla with a target price of $350.<br />
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Tesla, maintaining a target price of $313.<br />
&#x2A; An analyst from Jefferies persists with their Hold rating on Tesla, maintaining a target price of $300.<br />
&#x2A; An analyst from UBS persists with their Sell rating on Tesla, maintaining a target price of $226. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Tesla options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


What the Options Market Tells Us About Tesla

<p>Financial giants have made a conspicuous bullish move on Symbotic. Our analysis of options history for Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $210,224, and 4 were calls, valued at $196,187.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $22.0 to $37.5 for Symbotic over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Symbotic's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Symbotic's whale activity within a strike price range from $22.0 to $37.5 in the last 30 days. </p>
<h3>Symbotic Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732894306_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SYM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$22.00</td>
<td>$101.3K</td>
<td>108</td>
<td>1.0K</td>
</tr>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.4</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$25.00</td>
<td>$61.5K</td>
<td>1.3K</td>
<td>243</td>
</tr>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.6</td>
<td>$7.1</td>
<td>$7.25</td>
<td>$22.50</td>
<td>$53.6K</td>
<td>463</td>
<td>12</td>
</tr>
<tr>
<td>SYM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.75</td>
<td>$1.5</td>
<td>$1.5</td>
<td>$30.00</td>
<td>$45.0K</td>
<td>2.4K</td>
<td>294</td>
</tr>
<tr>
<td>SYM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$27.50</td>
<td>$41.0K</td>
<td>365</td>
<td>115</td>
</tr>
</tbody>
</table>
</p>
<h3>About Symbotic</h3>
<p>Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys innovative, end-to-end technology solutions that dramatically improve supply chain operations. Symbotic also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.</p>
<p>Having examined the options trading patterns of Symbotic, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Symbotic</h3>
<ul>
<li>With a trading volume of 3,288,012, the price of SYM is up by 6.44%, reaching $25.54.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Symbotic</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $43.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Symbotic, targeting a price of $46.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $60.<br />
&#x2A; Consistent in their evaluation, an analyst from BWS Financial keeps a Sell rating on Symbotic with a target price of $10.<br />
&#x2A; Consistent in their evaluation, an analyst from Northland Capital Markets keeps a Outperform rating on Symbotic with a target price of $53.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Symbotic with a target price of $48. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Symbotic, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Symbotic Unusual Options Activity

<p>Wedbush  analyst Yun Zhong   assumes Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) with a Outperform rating and announces Price Target of $4.</p>


PASG

Wedbush Assumes Passage Bio at Outperform, Announces Price Target of $4

BGM Group shares are trading higher after the company announced its acquisition of the intelligent platform of AIX Inc., valued at approximately $140 million.

<p>Developmental-stage biopharmaceutical company <strong>Silo Pharma, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares are<a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener"> trading higher on Friday</a>.</p>
<p>The company has announced a collaboration with Kymanox to develop a specialized subcutaneous insertion device for SP-26, its ketamine-loaded implant aimed at treating <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42243217/silo-pharma-enters-joint-development-agreement-for-sp-26-ketamine-implant-device-targeting-pain-ma" rel="noreferrer noopener">fibromyalgia and chronic pain</a>.</p>
<p>The agreement includes a proof-of-concept design phase followed by prototype testing to determine the optimal tissue insertion depth.</p>
<p>Silo Pharma&#8217;s CEO, Eric Weisblum, highlighted that previous trials have confirmed the implant&#8217;s optimal formulation, and the focus now shifts to refining the insertion device for preclinical studies.</p>
<p>&#8220;Now we are advancing this program to develop a novel insertion device that is intended to be tested in continuing preclinical studies,&#8221; Weisblum added.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42244387/nvidia-lam-reasearch-applied-materials-stocks-gain-as-biden-government-eyes-softer-semiconductor-sanctions-against-china" rel="noreferrer noopener">Nvidia, Chip Stocks Gain On Reports Of Softer China Sanctions</a></strong></p>
<p>If clinically successful, SP-26 could qualify for the FDA&#8217;s streamlined 505(b)(2) regulatory pathway for drug approval, the company said.</p>
<p>SP-26 is designed with the goal of meeting FDA safety standards for at-home use. In addition to the SP-26 project, Kymanox also serves as Silo&#8217;s regulatory partner for SPC-15, a treatment for stress-related disorders like PTSD.</p>
<p>According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SILO stock has lost over 39% in the past year.</p>
<p><strong>Price Action:</strong> SILO shares are trading higher by 6.68% to $0.9601 at last check Friday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/global/24/11/42198109/nvidia-blackwell-supplier-vishay-intertechnology-likey-to-see-upside-courtesy-of-ai-frenzy-analyst" target="_blank" rel="noreferrer noopener">Nvidia Blackwell Supplier Vishay Intertechnology Likely To See Upside Courtesy Of AI Frenzy: Analyst</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


SILO

Why Is Silo Pharma Stock Gaining Today?

<p>RBC Capital  analyst Paul Treiber   maintains Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) with a Outperform and raises the price target from $115 to $133.</p>


DSGX

RBC Capital Maintains Outperform on Descartes Systems Gr, Raises Price Target to $133

Trading Ideas

AIEV

Thunder Power Holdings Shares Halted On Circuit Breaker To Upside

<p>RBC Capital  analyst Brian Abrahams   downgrades Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Outperform to Sector Perform and lowers the price target from $12 to $4.</p>


Downgrades

APLT

RBC Capital Downgrades Applied Therapeutics to Sector Perform, Lowers Price Target to $4

<p><strong>Yum China Holdings, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) shares are trading slightly lower in the morning session on Friday.</p>
<p>The company is making significant strides in modernizing its supply chain with the official launch of its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42237680/yum-china-officially-launches-digital-supplier-recruitment-platform-at-china-international-supply-" rel="noreferrer noopener">digital supplier recruitment platform</a>.</p>
<p>Unveiled at the 2nd China International Supply Chain Expo, the platform invites high-quality enterprises globally to join the company&#8217;s expansive supply chain network.</p>
<p>This platform marks a shift from traditional supplier selection to a data-driven and interactive process. By enabling potential suppliers to submit their credentials online, Yum China simplifies the engagement process, significantly reducing the time and manual effort required for supplier evaluation.</p>
<p>It also promotes transparency and fairness in selection, aligning with the company&#8217;s &#8220;Spend Better, Buy Better&#8221; initiative aimed at enhancing operational efficiency.</p>
<p>Since its pilot launch in April 2024, the platform has already attracted applications across more than 30 categories, covering over a third of the company&#8217;s total categories.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42241785/us-futures-signal-gains-on-the-truncated-trading-day-will-december-witness-a-santa-claus-rally-analysts-decode" rel="noreferrer noopener">US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode</a></strong></p>
<p>At the launch ceremony, Yum China also signed agreements with both domestic and international companies, focusing on sourcing and product innovation to improve the culinary experience for its customers.</p>
<p>Yum China&#8217;s supply chain management system already includes over 800 core suppliers across diverse categories, such as food ingredients, beverages, and packaging materials. Leveraging this vast network, the company delivers safe and diverse menu options tailored to the tastes of Chinese consumers.</p>
<p>For FY24, Yum China plans to open 1,500 to 1,700 new stores, invest $700 million to $850 million in capital expenditures, and return $1.5 billion to shareholders <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41709548/yum-china-q3-earnings-surprise-kfc-pizza-hut-power-earnings-beat-reiterates-capex-plan-to-open-1-50" rel="noreferrer noopener">through dividends and share repurchases</a>.</p>
<p><strong>Price Action: </strong>YUMC shares are trading lower by 0.73% to $46.44 at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="http://gop%20megadonor%20ken%20griffin%20slashes%20citadel's%20palantir%20stake%20by%2091%25,%20bets%20big%20on%20nvidia%20as%20jensen%20huang-led%20company%20rises%20over%20180%25%20in%202024/" target="_blank" rel="noreferrer noopener">GOP Megadonor Ken Griffin Slashes Citadel&#8217;s Palantir Stake By 91%, Bets Big On Nvidia As Jensen Huang-Led Company Rises Over 180% In 2024</a></strong></li>
</ul>
<p><em>Photo by aleks-dorohovich- for Unsplash.</em></p>


YUMC

Yum China Unveils New Platform For Supplier Recruitment With Speed And Transparency

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Bank of America</strong>.</p>
<p>Looking at options history for Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 44% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $351,268 and 2, calls, for a total amount of $128,420.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $32.0 to $60.0 for Bank of America over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Bank of America stands at 5699.0, with a total volume reaching 4,464.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bank of America, situated within the strike price corridor from $32.0 to $60.0, throughout the last 30 days.</p>
<h3>Bank of America Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732893380_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.62</td>
<td>$0.6</td>
<td>$0.6</td>
<td>$45.00</td>
<td>$90.0K</td>
<td>3.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.0</td>
<td>$15.85</td>
<td>$16.0</td>
<td>$32.00</td>
<td>$80.0K</td>
<td>21.1K</td>
<td>50</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.21</td>
<td>$2.17</td>
<td>$2.2</td>
<td>$49.00</td>
<td>$50.6K</td>
<td>1.1K</td>
<td>679</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.6</td>
<td>$2.53</td>
<td>$2.6</td>
<td>$49.00</td>
<td>$50.1K</td>
<td>305</td>
<td>194</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.23</td>
<td>$2.18</td>
<td>$2.22</td>
<td>$49.00</td>
<td>$50.1K</td>
<td>1.1K</td>
<td>225</td>
</tr>
</tbody>
</table>
</p>
<h3>About Bank of America</h3>
<p>Bank of America is one of the largest financial institutions in the United States, with more than $3.0 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.</p>
<p>Having examined the options trading patterns of Bank of America, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Bank of America Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,021,732, the BAC's price is down by -0.01%, now at $47.77. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<h3>Professional Analyst Ratings for Bank of America</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $55.333333333333336.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a positive move, an analyst from Citigroup has upgraded their rating to Buy and adjusted the price target to $54.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Bank of America, which currently sits at a price target of $56.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Bank of America with a target price of $56. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bank of America with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Bank of America's Options Frenzy: What You Need to Know

<p>Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 14 unusual trades.</p>
<p>Delving into the details, we found 35% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $210,005, and 9 were calls, valued at $379,290.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $105.0 to $111.0 for Novo Nordisk over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $105.0 to $111.0, over the past month.</p>
<h3>Novo Nordisk 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732893375_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/13/24</td>
<td>$5.6</td>
<td>$5.05</td>
<td>$5.29</td>
<td>$105.00</td>
<td>$159.0K</td>
<td>171</td>
<td align="right">300</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$8.35</td>
<td>$8.0</td>
<td>$8.2</td>
<td>$110.00</td>
<td>$42.6K</td>
<td>7.0K</td>
<td align="right">273</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$110.00</td>
<td>$42.1K</td>
<td>7.0K</td>
<td align="right">116</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$110.00</td>
<td>$42.1K</td>
<td>7.0K</td>
<td align="right">64</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.7</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$109.00</td>
<td>$42.0K</td>
<td>351</td>
<td align="right">56</td>
</tr>
</tbody>
</table>
</p>
<h3>About Novo Nordisk</h3>
<p>With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.</p>
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 358,592, with NVO's price down by -0.65%, positioned at $105.44.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 61 days.</li>
</ul>
<h3>Expert Opinions on Novo Nordisk</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $160.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


What the Options Market Tells Us About Novo Nordisk

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Leap Therapeutics (LPTX – Research Report). The associated pr...

Buy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic Expansion

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Leap Therapeutics (LPTX – Research Report) on May 13 and set a price target of $9.00...

Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials

Leap Therapeutics GAAP EPS of -$0.52 misses by $0.09

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Leap Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lptx-stock-quote/"><strong>LPTX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Leap Therapeutics reported earnings per share of -52 cents. This was below the analyst estimate for EPS of -43 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/lptx-stock-earnings-leap-therapeutics-for-q2-of-2024/">LPTX Stock Earnings: Leap Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LPTX Stock Earnings: Leap Therapeutics Misses EPS for Q2 2024

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Leap Therapeutics (LPTX – Research Report) today and set a price target o...

Maintained Buy Rating for Leap Therapeutics Amid Promising Clinical and Financial Outlook

Robert W. Baird analyst Joel Beatty has maintained their bullish stance on LPTX stock, giving a Buy rating today. Joel Beatty's rating is based on ...

Optimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial Outcomes

Leap Therapeutics GAAP EPS of -$0.44 beats by $0.04

Leap Therapeutics ( ($LPTX) ) has released its Q3 earnings. Here is a breakdown of the information Leap Therapeutics presented to its investors. Le...

Leap Therapeutics Reports Q3 2024 Progress and Financials

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Leap Therapeutics (LPTX – Research Report), with...

Buy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial Outlook

Finding Winners In Biotech, Probably The Riskiest Sector

ABBV

AZNCF

BPMC

LPTX

STRO

SWTX

TARS

VYGR

Press Releases

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Comments

Leap Therapeutics

Leap Therapeutics (LPTX) Opzioni

Leap Therapeutics (NASDAQ:LPTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO